PDCD1 and non-small cell lung carcinoma: Thus, the impact of single agent anti-PD-1 or -PD-L1 therapy in advanced pretreated NSCLC appears to be greater in patients with a smoking history compared to those without compared to second-line chemotherapy (Figure 2).